{
    "medicine_id": "f3225d50165eb764d2c47b4ca9e95735a95fd36d",
    "platform_id": "DB13898",
    "metadata": {
        "name": "Bat Liquid",
        "composition": "Equine Botulinum Neurotoxin C Immune FAB2",
        "clinical_particulars": {
            "therapeutic_indications": "Equine Botulinum Neurotoxin C Immune FAB2 is indicted for use in documented or suspected exposure to botulinum toxin serotype C in adults and pediatric patients FDA Label",
            "contraindications": {
                "disease": "Equine Botulinum Neurotoxin C Immune FAB2 may produce anaphylaxis or anaphylactoid reactions particularly in patients who have previously been exposed to equine derived antivenom or antitoxins or patient with preexisting hypersensitivity to horses asthma or hay fever FDA Label Serum sickness reactions may present 10 21 days after infusion Various infusion reactions may occur dependent on the rate of infusion These include chills fever headaches nausea and vomiting Arthralgia myalgia and vasovagal reactions may also occur independently of infusion rate Because the antibodies are derived from equine plasma there is a risk of infectious disease transmission although this is controlled through manufacturing processes",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Equine Botulinum Neurotoxin C Immune FAB2 binds to botulinum toxin serotype C to prevent toxicity FDA Label",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}